|Other Names||Epsin-2, EPS-15-interacting protein 2, EPN2, KIAA1065|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2182a was selected from the N-term region of human Epsin2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Plays a role in the formation of clathrin-coated invaginations and endocytosis.|
|Cellular Location||Cytoplasm. Cytoplasmic vesicle, clathrin-coated vesicle. Note=In punctate structures throughout the cell, associated with clathrin-coated vesicles, and particularly concentrated in the region of the Golgi complex|
|Tissue Location||Highest expression is found in brain. Detected at lower levels in lung and liver.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Epsin2 plays a role in the formation of clathrin-coated invaginations and endocytosis. It binds to EPS15 (via the NPF repeat domain), as well as to AP-2 and clathrin (via the DPW repeat domain). The protein resides in the cytoplasm, in punctate structures throughout the cell, associated with clathrin-coated vesicles, and is particularly concentrated in the region of the Golgi complex. Highest expression is found in brain, with lower levels detected in lung and liver.
Ota, T., et al., Nat. Genet. 36(1):40-45 (2004).Kikuno, R., et al., DNA Res. 6(3):197-205 (1999).Rosenthal, J.A., et al., J. Biol. Chem. 274(48):33959-33965 (1999).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.